Crossmark

Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU

Crossref DOI link: https://doi.org/10.1186/s13023-019-1011-y

Published Online: 2019-02-15

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Daly, A. https://orcid.org/0000-0003-2579-8699
Evans, S.

Chahal, S.

Santra, S.

Pinto, A.

Jackson, R.

Gingell, C.

Rocha, J.

Van Spronsen, F. J.

MacDonald, A.
Funding

Funding for this research was provided by:

Vitaflo
License Information

Text and Data Mining valid from 2019-02-15
More Information

Article History

Received: 5 May 2018

Accepted: 28 January 2019

First Online: 15 February 2019

Authors’ information

: Authors information email and full names given on first page.

: We have gained Ethical approval and participant consent. The study was registered by the Health Research Authority and was given a favourable ethical opinion by the South Birmingham Research Ethical Committee. Ref nos 13/WM/0435.

: All subjects and authors have given informed consent for publication.

: The study was funded as part of PhD grant. The authors: Daly A, Evans S, Pinto A, Rocha J, MacDonald A have received research grants and lecturing honoraria, consulting fees from various nutritional companies (Nutricia Ltd., Vitaflo Ltd., Merck Serono, Bio-Marin, Firstplay dietary foods, Mevalia, Cambrook Foods, APR, Eurocept, Arla). Francjan van Spronsen Nutricia Ltd., Vitaflo Ltd., Merck Serono, BioMarin, APR, Eurocept, and Arla international. Gingell C, Santra S, Chahal S, Jackson A declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.